|
|
Last Modified: 12/24/2008  First Published: 9/24/2008 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Temporarily closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
UMN-2008LS035 UMN-2008LS035, UMN-0803M29541, NCT00769990
|
|
|
|
|
|
|
|
Last Modified: 6/10/2008  First Published: 3/24/2003 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NU-00U7 NCT00058266
|
|
|
|
|
|
|
|
Last Modified: 6/24/2008  First Published: 6/25/2005 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
WCCC-CO-04307 WCCC-UWI03-1-01, WCCC-H-2005-0026, NCT00118040
|
|
|
|
|
|
|
|
Last Modified: 1/8/2009  First Published: 10/21/2005 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
WSU-C-2597 NCT00244933
|
|
|
|
|
|
|
|
Last Modified: 1/14/2008  First Published: 1/6/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
NU-04V1 CHIR-NU-04V1, NU-IRB-0310-083, NCT00276835
|
|
|
|
|
|
|
|
Last Modified: 8/15/2008  First Published: 2/3/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Prevention
|
|
|
|
Closed
|
|
|
|
25 and older
|
|
|
|
NCI
|
|
|
|
NU-NWU03-1-04 NU-NCI-04B3, NU-0835-030, NCT00290758, NWU03-1-04
|
|
|
|
|
|
|
|
Last Modified: 8/23/2008  First Published: 9/10/2006 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Temporarily closed
|
|
|
|
21 and over
|
|
|
|
NCI
|
|
|
|
WSU-2005-006 WSU-025806MP4F, NCT00376948
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Biomarker/Laboratory analysis, Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
Other
|
|
|
|
P2BV10 NCT00546039
|
|
|
|
|
|
|
|
Last Modified: 5/1/2001  First Published: 8/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Prevention, Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
NCI-98-C-0099B
|
|
|
|
|
|
|
|
Last Modified: 6/12/2007  First Published: 6/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
40 and over
|
|
|
|
NCI
|
|
|
|
UNC-LCCC-9711 UNC-GCRC-1203, NCI-G00-1788, NCT00005827
|
|
|
|